BACKGROUND: Wilms tumor is the most common childhood kidney cancer. Two distinct histological subtypes of Wilms tumor have been described: tumors lacking anaplasia (the favorable subtype) and tumors displaying anaplastic features (the unfavorable subtype). Children with favorable disease generally have a very good prognosis, whereas those with anaplasia are oftentimes refractory to standard treatments and suffer poor outcomes, leading to an unmet clinical need. MYCN dysregulation has been associated with a number of pediatric cancers including Wilms tumor. PROCEDURES: In this context, we undertook a functional genomics approach to uncover novel therapeutic strategies for those patients with anaplastic Wilms tumor. Genomic analysis and in vitro experimentation demonstrate that cell growth can be reduced by modulating MYCN overexpression via bromodomain 4 (BRD4) inhibition in both anaplastic and nonanaplastic Wilms tumor models. RESULTS: We observed a time-dependent reduction of MYCN and MYCC protein levels upon BRD4 inhibition in Wilms tumor cell lines, which led to cell death and proliferation suppression. BRD4 inhibition significantly reduced tumor volumes in Wilms tumor patient-derived xenograft (PDX) mouse models. CONCLUSIONS: We suggest that AZD5153, a novel dual-BRD4 inhibitor, can reduce MYCN levels in both anaplastic and nonanaplastic Wilms tumor cell lines, reduces tumor volume in Wilms tumor PDXs, and should be further explored for its therapeutic potential.
BACKGROUND: Wilms tumor is the most common childhood kidney cancer. Two distinct histological subtypes of Wilms tumor have been described: tumors lacking anaplasia (the favorable subtype) and tumors displaying anaplastic features (the unfavorable subtype). Children with favorable disease generally have a very good prognosis, whereas those with anaplasia are oftentimes refractory to standard treatments and suffer poor outcomes, leading to an unmet clinical need. MYCN dysregulation has been associated with a number of pediatric cancers including Wilms tumor. PROCEDURES: In this context, we undertook a functional genomics approach to uncover novel therapeutic strategies for those patients with anaplastic Wilms tumor. Genomic analysis and in vitro experimentation demonstrate that cell growth can be reduced by modulating MYCN overexpression via bromodomain 4 (BRD4) inhibition in both anaplastic and nonanaplastic Wilms tumor models. RESULTS: We observed a time-dependent reduction of MYCN and MYCC protein levels upon BRD4 inhibition in Wilms tumor cell lines, which led to cell death and proliferation suppression. BRD4 inhibition significantly reduced tumor volumes in Wilms tumor patient-derived xenograft (PDX) mouse models. CONCLUSIONS: We suggest that AZD5153, a novel dual-BRD4 inhibitor, can reduce MYCN levels in both anaplastic and nonanaplastic Wilms tumor cell lines, reduces tumor volume in Wilms tumor PDXs, and should be further explored for its therapeutic potential.
Authors: Ariadne H A G Ooms; Samantha Gadd; Daniela S Gerhard; Malcolm A Smith; Jaime M Guidry Auvil; Daoud Meerzaman; Qing-Rong Chen; Chih Hao Hsu; Chunhua Yan; Cu Nguyen; Ying Hu; Yussanne Ma; Zusheng Zong; Andrew J Mungall; Richard A Moore; Marco A Marra; Vicki Huff; Jeffrey S Dome; Yueh-Yun Chi; Jing Tian; James I Geller; Charles G Mullighan; Jing Ma; David A Wheeler; Oliver A Hampton; Amy L Walz; Marry M van den Heuvel-Eibrink; Ronald R de Krijger; Nicole Ross; Julie M Gastier-Foster; Elizabeth J Perlman Journal: Clin Cancer Res Date: 2016-10-04 Impact factor: 12.531
Authors: Justine E Roderick; Jessica Tesell; Leonard D Shultz; Michael A Brehm; Dale L Greiner; Marian H Harris; Lewis B Silverman; Stephen E Sallan; Alejandro Gutierrez; A Thomas Look; Jun Qi; James E Bradner; Michelle A Kelliher Journal: Blood Date: 2014-01-06 Impact factor: 22.113
Authors: Jeffrey S Dome; Cecilia A Cotton; Elizabeth J Perlman; Norman E Breslow; John A Kalapurakal; Michael L Ritchey; Paul E Grundy; Marcio Malogolowkin; J Bruce Beckwith; Robert C Shamberger; Gerald M Haase; Max J Coppes; Peter Coccia; Morris Kletzel; Robert M Weetman; Milton Donaldson; Roger M Macklis; Daniel M Green Journal: J Clin Oncol Date: 2006-05-20 Impact factor: 44.544
Authors: G Gamberi; M S Benassi; T Bohling; P Ragazzini; L Molendini; M R Sollazzo; F Pompetti; M Merli; G Magagnoli; A Balladelli; P Picci Journal: Oncology Date: 1998 Nov-Dec Impact factor: 2.935
Authors: Pratiti Bandopadhayay; Guillaume Bergthold; Brian Nguyen; Simone Schubert; Sharareh Gholamin; Yujie Tang; Sara Bolin; Steven E Schumacher; Rhamy Zeid; Sabran Masoud; Furong Yu; Nujsaubnusi Vue; William J Gibson; Brenton R Paolella; Siddhartha S Mitra; Samuel H Cheshier; Jun Qi; Kun-Wei Liu; Robert Wechsler-Reya; William A Weiss; Fredrik J Swartling; Mark W Kieran; James E Bradner; Rameen Beroukhim; Yoon-Jae Cho Journal: Clin Cancer Res Date: 2013-12-02 Impact factor: 12.531
Authors: Trevor J Pugh; Olena Morozova; Edward F Attiyeh; Shahab Asgharzadeh; Jun S Wei; Daniel Auclair; Scott L Carter; Kristian Cibulskis; Megan Hanna; Adam Kiezun; Jaegil Kim; Michael S Lawrence; Lee Lichenstein; Aaron McKenna; Chandra Sekhar Pedamallu; Alex H Ramos; Erica Shefler; Andrey Sivachenko; Carrie Sougnez; Chip Stewart; Adrian Ally; Inanc Birol; Readman Chiu; Richard D Corbett; Martin Hirst; Shaun D Jackman; Baljit Kamoh; Alireza Hadj Khodabakshi; Martin Krzywinski; Allan Lo; Richard A Moore; Karen L Mungall; Jenny Qian; Angela Tam; Nina Thiessen; Yongjun Zhao; Kristina A Cole; Maura Diamond; Sharon J Diskin; Yael P Mosse; Andrew C Wood; Lingyun Ji; Richard Sposto; Thomas Badgett; Wendy B London; Yvonne Moyer; Julie M Gastier-Foster; Malcolm A Smith; Jaime M Guidry Auvil; Daniela S Gerhard; Michael D Hogarty; Steven J M Jones; Eric S Lander; Stacey B Gabriel; Gad Getz; Robert C Seeger; Javed Khan; Marco A Marra; Matthew Meyerson; John M Maris Journal: Nat Genet Date: 2013-01-20 Impact factor: 38.330
Authors: Shaokun Shu; Charles Y Lin; Housheng Hansen He; Robert M Witwicki; Doris P Tabassum; Justin M Roberts; Michalina Janiszewska; Sung Jin Huh; Yi Liang; Jeremy Ryan; Ernest Doherty; Hisham Mohammed; Hao Guo; Daniel G Stover; Muhammad B Ekram; Jonathan Brown; Clive D'Santos; Ian E Krop; Deborah Dillon; Michael McKeown; Christopher Ott; Jun Qi; Min Ni; Prakash K Rao; Melissa Duarte; Shwu-Yuan Wu; Cheng-Ming Chiang; Lars Anders; Richard A Young; Eric Winer; Antony Letai; William T Barry; Jason S Carroll; Henry Long; Myles Brown; X Shirley Liu; Clifford A Meyer; James E Bradner; Kornelia Polyak Journal: Nature Date: 2016-01-06 Impact factor: 49.962
Authors: Cho-Hao Lin; Jimmy Chun-Tien Kuo; Ding Li; Aaron B Koenig; Alexander Pan; Pearlly Yan; Xue-Feng Bai; Robert J Lee; Kalpana Ghoshal Journal: Front Cell Dev Biol Date: 2022-03-24